Home › NDC Lookup › J-codes › J0699
J0699

J0699 – Injection, cefiderocol, 10 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 1 NDC crosswalked per 10 mg $2.548/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J0699 summary

J0699 is a HCPCS Level II J-code used to bill cefiderocol, 10 mg, billed per 10 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J0699: Fetroja

Code J0699 Billing unit 10 mg Payment limit $2.548/unit NDC-Crosswalk 1 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ0699
DescriptorInjection, cefiderocol, 10 mg
Billing unit10 mg
Payment limit / unit$2.548
Est. ASP / unit$2.404 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20

💊 About Cefiderocol Injection DRUG GUIDE

Fetroja (cefiderocol) is approved for adults 18 and older to treat two types of serious infections caused by susceptible gram-negative bacteria.

The first is complicated urinary tract infections (cUTIs), including kidney infections (pyelonephritis), caused by organisms such as E.

coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.The second is hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), caused by gram-negative bacteria including Acinetobacter baumannii complex, E.

coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.

Read the full Cefiderocol Injection drug guide →
Clinical overview from our editorial drug guide for Cefiderocol Injection. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.548
Est. ASP / unit
$2.404 est.
Est. after 2% sequester
$2.497
HCPCS dosage
10 mg
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, cefiderocol, 10 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2021-10-01
Date added2021-10-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J0699 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J0699 WITH EST. MEDICARE PAY

1 NDC map to J0699. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.548/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
59630-0266-10 Fetroja Cefiderocol sulfate tosylate 1 g/10mL INJECTION, POWDER, FOR SOLUTION Shionogi 10 VIAL, SINGLE-USE in 1 CARTON (59630-266... 1 g/10mL 1,000 $2,548.00 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend
$85.9K
Claims
85
Beneficiaries
31
Spend / beneficiary
$2,770.33
Spend / claim
$1,010.36
Where J0699 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #699 of 918
#694 THROMBATE III J7197 $88.5K #695 ZENITH AMNIOTIC MEMB... Q4253 $88.3K #696 IMIPENEM-CILASTATIN... J0743 $87.6K #697 CORTROSYN* J0834 $87K #698 MULTIHANCE MULTIPACK A9578 $86.1K #699 FETROJA J0699 $85.9K #700 DAPTOMYCIN(J0873) J0873 $84K #701 CLONIDINE HCL* J0735 $83.3K #702 PEMETREXED(J9323) J9323 $78.7K #703 MOXIFLOXACIN J2280 $76.1K #704 IBANDRONATE SODIUM J1740 $75.3K
Total claims — #811 of 918
#806 TYZAVAN* J3375 90 #807 LAMZEDE J0217 89 #808 HEPZATO J9248 89 #809 ALDURAZYME J1931 86 #810 ALPHANINE SD J7193 86 #811 FETROJA J0699 85 #812 BENTYL* J0500 83 #813 HYPERHEP B* 90371 82 #814 PROGENAMATRIX, PER S... Q4222 82 #815 BICNU* J9050 81 #816 MATRISTEM MICROMATRI... Q4118 80

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2025 (Q1-Q4) $85.9K 31 85 $2,770.33 $1,010.36
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$60.3K
Medicare paid
$47.3K
Submitted services
341,846
Denial rate
92.6%
Allowed / service
$2.37
Submitted charges
$3.08M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J0699 billing FAQ

What is HCPCS code J0699?
J0699 is a HCPCS Level II J-code used to bill Injection, cefiderocol, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0699?
One unit of J0699 represents 10 mg. Report the number of units equal to the dose administered divided by 10 mg.
How many units of J0699 should I bill?
Divide the dose administered by the code's unit size (10 mg) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0699?
The Medicare Part B payment limit is $2.548 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.497 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0699?
1 NDC currently map to J0699 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0699 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.